Evidence from human observational studies and clinical trials indicates that n-3 fatty acids can protect against fatal heart disease by preventing cardiac arrhythmias (Burr et al. 1989; Albert et al. 2002; Marchioli et al. 2002) . In addition, experimental studies show that n-3 fatty acids prevent and terminate arrhythmias in in vitro and animal models. n-3 Fatty acids stabilize the electrical activity of cardiomyocytes by elevating the action potential threshold and prolonging the relative refractory time. These effects may result from an action of n-3 fatty acids on ion transport through heart cell membranes, which is essential for heart rhythm (Kang & Leaf, 2000) . Effects on the electrophysiology of the whole heart may be demonstrable in a surface electrocardiogram (ECG) in man. We previously reported no effect of n-3 fatty acids on several ECG characteristics in healthy subjects (Geelen et al. 2002) . However, effects of n-3 fatty acids may be detected only in abnormal ECG of more susceptible subjects. We therefore performed a study in patients with frequent premature ventricular complexes, a common form of arrhythmia that may trigger more life-threatening arrhythmias.
The heart-rate-corrected QT interval (QTc) on the ECG is a relevant measure for arrhythmia risk. In the general population, subjects with a longer QTc have an increased mortality risk (Schouten et al. 1991; Dekker et al. 1994; de-Bruyne et al. 1999) . Thus, a decrease in QTc by n-3 fatty acids would support a protective effect of n-3 fatty acids on heart disease. An earlier study showed that n-3 fatty acids decreased the duration of QTc in dogs (Billman et al. 1997) . n-3 Fatty acids may also affect other more exploratory ECG characteristics. For instance, T-loop width ) and the spatial QRS-T angle (Kardys et al. 2003) have been proposed as markers for heterogeneity of ventricular repolarization, which provides the condition for the genesis of ventricular arrhythmias. The spatial QRS-T angle has been recognized as a risk predictor of cardiac mortality in the elderly (Kardys et al. 2003) . Furthermore, U-wave changes may predict the occurrence of arrhythmias (Trusz-Gluza et al. 2002) , although little is known about the origin and physiological meaning of the U-wave. In an earlier study on the effects of n-3 fatty acids on ECG characteristics (Geelen et al. 2002) , we found a tendency for n-3 fatty acids to decrease the U-wave (S Quak, A Geelen, IA Brouwer, PL Zock, HJ Ritsema van Eck, JA Kors, MB Katan and EG Schouten, unpublished results) . Effects of n-3 fatty acids on specific ECG characteristics could provide insight into the mechanism of a possible antiarrhythmic effect. It could also suggest new biomarkers for the study of the antiarrhythmic potential of drugs and food ingredients in man. Therefore, we investigated the effect of intake of very long-chain n-3 fatty acids from fish on QTc, T-loop width, spatial QRS-T angle and spatial U-wave amplitude in subjects with frequent premature ventricular complexes.
Subjects and methods
The Medical Ethical Committee of Wageningen University approved the study protocol. Patients gave their written informed consent after the study protocol had been explained to them. Cardiologists from three Dutch hospitals recruited and enrolled patients aged 18 years or older with at least 1440 premature ventricular complexes per 24 h in a previous Holter recording made less than 6 months before the study. We included patients with and without a history of myocardial infarction, but patients who used antiarrhythmic drugs other than beta-blockers were excluded. Ninety-two patients who met the inclusion criteria were randomized, of whom eighty-four successfully completed the study.
The primary purpose of the present double-blind, placebocontrolled study with parallel design was to investigate effects of n-3 fatty acids on the occurrence of premature ventricular complexes (results reported elsewhere). Patients were randomized per centre, stratified for history of myocardial infarction, to receive either a daily dose of 3·5 g fish oil or placebo oil (high oleic sunflower oil; Loders Croklaan, Wormerveer, The Netherlands) during the intervention period of 14 (SD 1) weeks. The oils were administered in seven soft gelatin capsules daily (Banner Pharmacaps Europe BV, Tilburg, The Netherlands). Fish oil capsules provided approximately 700 mg EPA (C20 : 5n-3), 560 mg DHA (C22 : 6n-3) and 260 mg other n-3 fatty acids per d. The placebo capsules contained mainly oleic acid (C18 : 1n-9).
Compliance of the patients was checked by analysis of n-3 fatty acids in serum cholesteryl esters from non-fasting blood samples taken at the beginning and end of the intervention period (Zock et al. 1997) . Intakes of energy, fatty acids, cholesterol and alcohol were estimated by a telephone-administered 24 h dietary recall. In addition, fish intake was assessed twice by interviewing patients using a questionnaire on the frequency of fish consumption.
Complete ECG measurements at both baseline and the end of the intervention period were available for seventy-four patients. Standard twelve-lead ECG were recorded for 1 min with a Cardio Perfect Portable recorder and digitally stored on a Cardio Control workstation (Cardio Control NV, Delft, The Netherlands). We processed ECG recordings without knowledge of treatment type or other subject variables, using the Modular ECG Analysis System (MEANS; van-Bemmel et al. 1990 ). Bazett's formula (QTc¼ QT/ p RR) was used to correct QT duration for heart rate. T-loop width and QRS-T angle were determined as described previously Kardys et al. 2003) . The amplitude of the spatial U-wave gradient vector was calculated by taking the integral of the x, y and z component of the U-wave using the interactive computer program 'Intraval' (Ritsema van Eck, 2004) .
Differences in response between the fish oil and placebo groups were analysed by Student's t test. A subgroup analysis for patients with and without prior myocardial infarction was planned beforehand and included in the protocol.
Results
There were no substantial differences in baseline characteristics between the fish oil and the placebo group (Table 1) . EPA in serum cholesteryl esters (g/100 g total fatty acids) confirmed compliance; it changed during intervention from 1·30 (SD 0·78) to 3·66 (SD 1·68) in the fish oil group and remained constant in the placebo group (1·03 (SD 0·70) to 0·98 (SD 0·62)). QTc was not significantly affected by intake of n-3 fatty acids; it decreased by 0·3 ms (95 % CI 10·7, 10·1 ms) or 0·1 % in the fish oil group compared with placebo ( Fig. 1, Table 2 ). Intake of n-3 fatty acids also did not significantly affect T-loop width, spatial QRS-T angle and spatial U-wave amplitude (Table 2) . Subgroup analyses in patients with and without prior myocardial infarction also revealed no significant effects (Table 2) .
Background dietary intake was similar in the two treatment groups. The fish oil group consumed 33 % energy as fat, 0·6 % energy (1·5 g/d) as total n-3 fatty acids (mostly a-linolenic acid), 4 % energy as alcohol and 23 mg cholesterol/MJ. In the placebo group the corresponding figures were 33 %, 0·5 % (1·1 g), 4 % and 28 mg/MJ. Fish intake was similar in the treatment groups and did not change during the intervention.
Discussion
We observed no effect of a daily intake of 3·5 g fish oil for approximately 14 weeks v. placebo on QTc, QRS-T angle, T-loop width or spatial U-wave amplitude in these patients with frequent premature ventricular complexes. It is unlikely that this is caused by a lack of power, because the 95 % CI of the difference in response of QTc was narrow. A true effect of n-3 fatty acids on QTc of more than 2·5 % is not expected. In a previous study, we also observed no effect of n-3 fatty acids on several ECG characteristics in eighty-four healthy middle-aged men and women (Geelen et al. 2002) . The effects of n-3 fatty acids on the electrophysiology of the human heart may be too small to cause appreciable ECG changes or there may be multiple effects at the cellular level that cancel each other out in the ECG. A standard ECG of short duration (1 min) may not be useful to demonstrate possible effects of n-3 fatty acids on the heart.
Protective effects of n-3 fatty acids on hard endpoints in clinical trials have been found exclusively for post-myocardial History of myocardial infarction, n (%)
11 ( It could be hypothesized that the cardioprotective effect of n-3 fatty acids is restricted to patients with earlier myocardial infarction. n-3 Fatty acids may interact with structural abnormalities in cardiac tissue due to previous infarctions and in that way prevent fatal arrhythmias. If so, n-3 fatty acids would affect the ECG only in post-infarction patients. We did not find effects of n-3 fatty acids on the ECG in our subgroup of such patients; however, this group was small (n 19). The dose of 3·5 g fish oil in the present study provided approximately 1·5 g n-3 fatty acids daily. Several observational studies suggest that the cardioprotective effect is already present at low doses of about 200 mg n-3 fatty acids/d. Most importantly, in the GISSI-Prevenzione trial, 1 g n-3 fatty acids/d was enough to lower the rate of death, non-fatal myocardial infarction and stroke (GISSI-Prevenzione Investigators, 1999) . Thus, it is highly unlikely that the dose of n-3 fatty acids in the present study was too low to detect relevant effects on the ECG, if any exist.
A definitive answer as to whether n-3 fatty acids can reduce risk of ventricular arrhythmia will have to come from long-term trials on n-3 fatty acids and arrhythmia incidence in high-risk patients with an implantable cardioverter defibrillator (Brouwer et al. 2003) . We are aware of three such trials; the first in 200 such patients recently reported a trend towards increased rather than decreased recurrence of ventricular arrhythmias in patients who received n-3 fatty acids over a follow-up of 2 years (Cleland et al. 2004) . Two other trials are running and will report within 2 years.
Despite the body of evidence that n-3 fatty acids reduce risk of fatal heart disease by preventing ventricular arrhythmia, we could not demonstrate effects on cardiac electrophysiology as measured in body surface ECG. The present results do not provide additional support for the hypothesis that n-3 fatty acids prevent cardiac arrhythmia through generic electrophysiologic effects on heart cell membranes. However, we cannot exclude effects of n-3 fatty acids on clinical relevant endpoints that are not easily detected by prior changes in the ECG. Mechanistic studies at the organ level and clinical trials on endpoints will have to provide conclusive answers. QTc, heart-rate-corrected QT duration.
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